Serina Therapeutics, Inc. (SER) - מזומן למניה

Serina Therapeutics, Inc. (SER) is developing a polymer drug delivery system for the treatment of neurological pathologies. The current cash per share, with GURU.Markets data illustrated on this chart, equals 0.72. This is supported by the implementation of POZ technology for rare injections and the availability of a proprietary, patent-protected POZ-GK platform, although final profit depends on clinical trial results.
פילוחי מדדים מקיפים ואנליטיקה עבור serinatherapeutics.com (SER)

For Serina Therapeutics, Inc. (SER), which develops costly polymer drug delivery technologies, liquidity is critical for sustaining preclinical research. This metric is calculated by dividing total cash reserves by the number of shares outstanding. Analyzing cash per share allows for an assessment of the real value of the liquid collateral backing each security. This determines the company's resilience to market shocks. A high cash level guarantees the issuer's survival during the prolonged development of therapies.